This proposal is submitted as a competing renewal of R01DA11602, """"""""HIV Disease Outcomes in Drug Users in Clinical Practice."""""""" This research is based in the Johns Hopkins HIV Clinical Cohort (JHHCC), established in to investigate HIV therapeutics and disease progression in clinical practice, with a special focus on injecting drug using (IDU) and non-IDU patients. Since the introduction of HAART in the U.S., HIV infection has largely evolved into a chronic disease. HIV/AIDS research questions have also evolved as the epidemic has matured. Before HAART, our research found comparability in disease progression between IDU and non-IDU patients. We demonstrated an early reduction in AIDS and mortality among both groups after HAART was introduced. During the past 5 years, our research has shown that IDU is a significant barrier to receiving and adhering to HAART, to achieving effective viral and immunologic improvement on HAART, and to attaining the cprominent than we have seen before, i.e., liver, renal, cardiovascular and metabolic diseases, and malignancy. Long-term survival with HIV and exposure to antiretrovirals, an aging host population, and long-term use of illicit drugs may all contribute to the incidence of these comorbidities, and raises new questions about the clinical course of non-AIDS-related morbidity and mortality among IDUs and non-IDUs.
Our specific aims are to, 1) Evaluate HIV disease progression among IDU and non-IDU patients as the HIV epidemic continues to mature and change in the setting of continuing advances in HAART and in the context of the clinical epidemiology of IDU, and, 2) Characterize the development and progression of non-AIDS related illnesses among IDU and non-IDU patients in the setting of longer survival, long-term antiretroviral exposure, an aging population, and in the context of relapse and remission of IDU, 3) Characterize HIV disease progression the viral hepatitis co-infected patient, d treatment for AIDS, the JHHCC is in an excellent position to identify emerging challenges for medical management of HIV infection and co-infections associated with drug addiction and the long-term consequences of HAART.

Public Health Relevance

Modern HIV therapy has allowed people with HIV infection to live longer lives, but the benefits may be less in patients who have injected drugs than in others. Non-AIDS related illnesses may also be occurring at higher rates than might otherwise be expected. We propose to study to compare the outcomes of HIV therapy in injecting drug using vs. non-drug using patients as the use of highly active antiretroviral therapy is now in its second decade.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Lambert, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dubrow, Robert; Qin, Li; Lin, Haiqun et al. (2017) Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr 75:382-390
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Drozd, Daniel R; Kitahata, Mari M; Althoff, Keri N et al. (2017) Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 75:568-576
Jiamsakul, Awachana; Kariminia, Azar; Althoff, Keri N et al. (2017) HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration. J Acquir Immune Defic Syndr 76:319-329
Muzaale, A D; Althoff, K N; Sperati, C J et al. (2017) Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors. Am J Transplant 17:1823-1832
Buchacz, Kate; Lau, Bryan; Jing, Yuezhou et al. (2016) Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis 214:862-72
Rebeiro, Peter F; Gange, Stephen J; Horberg, Michael A et al. (2016) Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One 11:e0146119
Pettit, April C; Mendes, Adell; Jenkins, Cathy et al. (2016) Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 72:572-8
Rachlis, Beth; Karwa, Rakhi; Chema, Celia et al. (2016) Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Saf 39:959-76
Haines, Charles F; Fleishman, John A; Yehia, Baligh R et al. (2016) Closing the Gap in Antiretroviral Initiation and Viral Suppression: Time Trends and Racial Disparities. J Acquir Immune Defic Syndr 73:340-347

Showing the most recent 10 out of 199 publications